SCHEMBL9892553

SCHEMBL9892553

N=C(N)OCCc1cc(F)c(Oc2cnc(C(F)(F)F)nc2)c(F)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9889536 0.85 GRM2 (0.33)
SCHEMBL9892536 0.85 S1PR1 (0.34)
SCHEMBL9106578 0.81 FAAH (0.37)
SCHEMBL9106106 0.81 FFAR4 (0.35)
SCHEMBL876627 0.78 KIF11 (0.33)
SCHEMBL9108123 0.76 PLA2G7 (0.46)
SCHEMBL9107997 0.75 PLA2G7 (0.32)
SCHEMBL9108005 0.75 PLA2G7 (0.35)
Trifluoromethanesulfonic Acid SCHEMBL9103515 0.71 SCN9A (0.43)
SCHEMBL9889455 0.71 GPR84 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8637536-B2 Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 GLAXO GROUP LIMITED (GB) 2014-01-28 US disclosed
WO-2012076435-A1 PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 GLAXO GROUP LIMITED (GB) 2012-06-14 WO disclosed
US-20120142717-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-06-07 US disclosed